Pain of skin adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 26,626 adverse event reports that record the MedDRA preferred term Pain of skin. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 1,181 reports in the 12 months to June 2026 and 1,071 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 545 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 1,181 (0.1%) record this term. Reports for female patients were 69% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 147 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Pain of skin name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		38
Actemra	Interleukin-6 receptor antagonist	43
Adapalene	Retinoid	83
Aimovig		39
Allopurinol	Xanthine oxidase inhibitor	39
Amlodipine	Calcium channel blocker	37
Apixaban	Factor Xa inhibitor	379
Astrazeneca Covid-19 Vaccine		335
Atorvastatin		42
Aubagio	Pyrimidine synthesis inhibitor	28
Avonex	Interferon beta	102
Bisoprolol	beta-Adrenergic blocker	105
Bisoprolol fumarate	beta-Adrenergic blocker	299
Botox	Acetylcholine release inhibitor	28
Cabometyx	Kinase inhibitor	102
Candesartan	Angiotensin 2 receptor blocker	272
Candesartan cilexetil	Angiotensin 2 receptor blocker	161
Capecitabine	Nucleoside metabolic inhibitor	33
Cetirizine	Histamine-1 receptor antagonist	151
Cetirizine hydrochloride	Histamine-1 receptor antagonist	249
Ciclosporin		32
Ciprofloxacin	Fluoroquinolone antibacterial	87
Citalopram	Serotonin reuptake inhibitor	29
Clindamycin	Lincosamide antibacterial	25
Clobetasol		52
Clopidogrel	P2Y12 platelet inhibitor	27
Cosentyx	Interleukin-17A antagonist	698
Covid-19 Vaccine		25
Cyclophosphamide	Alkylating drug	39
Cyclosporine	Calcineurin inhibitor immunosuppressant	98
Cymbalta		26
Dapagliflozin	Sodium-Glucose cotransporter 2 inhibitor	381
Diclofenac	Nonsteroidal anti-inflammatory drug	25
Differin	Retinoid	405
Digoxin	Cardiac glycoside	383
Docetaxel	Microtubule inhibitor	32
Doxycycline	Tetracycline-class drug	29
Dupilumab	Interleukin-4 receptor alpha antagonist	50
Dupixent	Interleukin-4 receptor alpha antagonist	1,314
Eliquis	Factor Xa inhibitor	49
Enbrel	Tumor necrosis factor blocker	408
Epiduo		56
Epiduo Forte	Retinoid	31
Erbitux	Epidermal growth factor receptor antagonist	27
Esomeprazole	Proton pump inhibitor	287
Esomeprazole magnesium	Proton pump inhibitor	84
Eucrisa	Phosphodiesterase 4 inhibitor	31
Felodipine	Dihydropyridine calcium channel blocker	380
Fluorouracil	Nucleoside metabolic inhibitor	33
Folic acid		35
Forteo	Parathyroid hormone analog	69
Furosemide	Loop diuretic	35
Gabapentin	Anti-epileptic agent	66
Gilenya	Sphingosine 1-phosphate receptor modulator	32
Herceptin	HER2/neu receptor antagonist	33
Humira		947
Hydrochlorothiazide	Thiazide diuretic	387
Hydrocortisone	Corticosteroid	55
Ibrance	Kinase inhibitor	123
Ibuprofen	Nonsteroidal anti-inflammatory drug	55
Imbruvica	Kinase inhibitor	46
Imdur		355
Incivek		33
Inflectra	Tumor necrosis factor blocker	32
Infliximab	Tumor necrosis factor blocker	35
Isosorbide dinitrate	Nitrate vasodilator	358
Isosorbide mononitrate	Nitrate vasodilator	368
Jakafi	Janus kinase inhibitor	30
Kesimpta	CD20-directed cytolytic antibody	38
Ketoconazole	Azole antifungal	25
Keytruda	Programmed death Receptor-1 blocking antibody	33
Kisqali	Kinase inhibitor	57
Lamictal	Anti-epileptic agent	28
Lansoprazole	Proton pump inhibitor	394
Leflunomide	Antirheumatic agent	26
Levothyroxine		61
Levothyroxine sodium	l-Thyroxine	329
Linagliptin	Dipeptidyl peptidase 4 inhibitor	374
Lyrica		80
Magnevist		68
Mens Rogaine Extra Strength		103
Metformin	Biguanide	61
Methotrexate	Folate analog metabolic inhibitor	342
Methotrexate sodium	Folate analog metabolic inhibitor	60
Metoprolol	beta-Adrenergic blocker	35
Mirena	Progestin	27
Mirvaso	alpha-Adrenergic agonist	61
Mirvaso Topical Gel 0 33%		49
Mounjaro	GLP-1 receptor agonist	103
MultiHance	Gadolinium-based contrast agent	37
Naproxen	Nonsteroidal anti-inflammatory drug	383
Nemluvio		75
Neulasta	Leukocyte growth factor	31
Nexavar	Kinase inhibitor	198
Niaspan		119
Ocrevus	CD20-directed cytolytic antibody	47
Omalizumab	Anti-IgE	56
Omeprazole	Proton pump inhibitor	69
Omniscan	Paramagnetic contrast agent	61
Optimark		43
Otezla	Phosphodiesterase 4 inhibitor	56
Ozempic	GLP-1 receptor agonist	71
Paclitaxel	Microtubule inhibitor	38
Pegasys	Interferon alpha	72
Pomalyst	Thalidomide analog	34
Prednisolone	Corticosteroid	50
Prednisone	Corticosteroid	173
Proactiv Solution Daily Protection Plus Sunscreen Spf 30		1,018
ProHance	Paramagnetic contrast agent	32
Prolia	RANK ligand inhibitor	98
Protopic		26
Qinlock	Kinase inhibitor	38
Ramipril	Angiotensin converting enzyme inhibitor	39
Remicade	Tumor necrosis factor blocker	62
Repatha	PCSK9 inhibitor	31
Revlimid	Thalidomide analog	117
Ribavirin	Nucleoside analog antiviral	63
Rinvoq	Janus kinase inhibitor	115
Rituximab	CD20-directed cytolytic antibody	39
Sertraline	Serotonin reuptake inhibitor	31
Simcor		36
Simvastatin	HMG-CoA reductase inhibitor	377
Skyrizi	Interleukin-23 antagonist	141
Soolantra	Antiparasitic	43
Spironolactone	Aldosterone antagonist	35
Stelara	Interleukin-12 antagonist	35
Stivarga	Kinase inhibitor	87
Sutent	Kinase inhibitor	67
Tapinarof		40
Tarceva		48
Tasigna	Kinase inhibitor	64
Tecfidera		84
Tri-Luma	Corticosteroid	27
Triamcinolone		36
Tykerb	Kinase inhibitor	29
Tysabri	Integrin receptor antagonist	68
Valchlor	Alkylating drug	44
Vectibix	Epidermal growth factor receptor antagonist	84
Wegovy	GLP-1 receptor agonist	97
Womens Rogaine		51
Womens Rogaine Unscented	Arteriolar vasodilator	91
Xeljanz	Janus kinase inhibitor	92
Xeloda	Nucleoside metabolic inhibitor	42
Xolair	Anti-IgE	91
Zepbound	GLP-1 receptor agonist	107
Zocor	HMG-CoA reductase inhibitor	37
Zoryve	Phosphodiesterase 4 inhibitor	32

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 53 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Pain of skin name, in order of name
Class	Reports with this term
Acetylcholine release inhibitor	52
Alkylating drug	88
alpha-Adrenergic agonist	61
Angiotensin 2 receptor blocker	477
Angiotensin converting enzyme inhibitor	53
Anti-epileptic agent	113
Anti-IgE	147
Aromatase inhibitor	63
Arteriolar vasodilator	105
beta-Adrenergic blocker	466
Biguanide	76
Calcineurin inhibitor immunosuppressant	152
Cardiac glycoside	383
CD20-directed cytolytic antibody	139
Corticosteroid	463
Dihydropyridine calcium channel blocker	392
Dipeptidyl peptidase 4 inhibitor	380
Epidermal growth factor receptor antagonist	115
Factor Xa inhibitor	460
Fluoroquinolone antibacterial	114
Folate analog metabolic inhibitor	402
GLP-1 receptor agonist	432
HER2/neu receptor antagonist	80
Histamine-1 receptor antagonist	424
HMG-CoA reductase inhibitor	457
Integrin receptor antagonist	89
Interferon alpha	74
Interferon beta	121
Interleukin-17A antagonist	722
Interleukin-23 antagonist	162
Interleukin-4 receptor alpha antagonist	1,364
Interleukin-6 receptor antagonist	61
Janus kinase inhibitor	270
Kinase inhibitor	1,056
l-Thyroxine	347
Microtubule inhibitor	85
Nitrate vasodilator	732
Nonsteroidal anti-inflammatory drug	526
Nucleoside analog antiviral	65
Nucleoside metabolic inhibitor	120
Paramagnetic contrast agent	93
Parathyroid hormone analog	69
Phosphodiesterase 4 inhibitor	87
Progestin	58
Programmed death Receptor-1 blocking antibody	74
Proton pump inhibitor	896
RANK ligand inhibitor	116
Retinoid	500
Serotonin reuptake inhibitor	97
Sodium-Glucose cotransporter 2 inhibitor	402
Thalidomide analog	171
Thiazide diuretic	387
Tumor necrosis factor blocker	605

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Pain of skin, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Pain of skin
Age	Reports	Share
Under 2	14	0.1%
2 to 11	274	1%
12 to 17	3,117	11.7%
18 to 44	6,486	24.4%
45 to 64	4,318	16.2%
65 to 74	1,877	7%
75 and over	1,093	4.1%
Age not given	9,447	35.5%

Sex of the patient in the reports that record Pain of skin
Sex	Reports	Share
Female	18,364	69%
Male	5,801	21.8%
Unknown or not given	2,461	9.2%

Age and sex are as the report gives them. 84.3% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Embed this card on your site

Copy this code into your page. The card shows the figures above with their source. A line under the card links to this page.

<iframe src="https://reportedreactions.com/embed/reaction/pain-of-skin/" title="Pain of skin: adverse event reports that record this term" width="100%" height="360" style="border:0;max-width:640px" loading="lazy"></iframe>
<p style="margin:4px 0 0;font-size:13px"><a href="https://reportedreactions.com/reaction/pain-of-skin/">Pain of skin: adverse event reports that record this term</a>, from reportedreactions.com</p>

How embedding works. It is free. Keep the link in the card and the link line under it.

Reported Reactions. Pain of skin: adverse event reports that record this term. https://reportedreactions.com/reaction/pain-of-skin/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Pain of skin mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page